CAR-T 세포 치료 시장 : 시장 규모, 예측, 임상시험 및 동향(2026-27년)

CAR-T REPORT EXECUTIVE SUMMARY

CAR-T cell therapy is a groundbreaking advancement in cancer treatment, offering remarkable promise for patients. This form of immunotherapy utilizes the power of the body's own immune cells, modifying them in a lab to enhance their ability to recognize and destroy cancer cells. Once infused back into the patient, these engineered cells multiply and persist in the body as "living drugs," continually working to fight the disease.

Global Regulatory Approvals

Since 2017, 16 CAR-T cell therapies have reached commercialization across multiple healthcare markets, up from 13 just a year ago. Seven therapies have been approved by the U.S. FDA. These therapies include:

• 1. Kymriah (tisagenlecleucel)
• 2. Yescarta (axicabtagene ciloleucel)
• 3. Tecartus (brexucabtagene autoleucel)
• 4. Breyanzi (lisocabtagene maraleucel)
• 5. Abecma (idecabtagene vicleucel)
• 6. Carvykti (ciltacabtagene autoleucel)
• 7. Aucatzyl (obecabtagene autoleucel)

Beyond the U.S., six CAR-T therapies (Carteyva, Yikaida, Zevor-cel, Yorwida, Fucaso, and Satri-cel) have been approved by China's National Medical Products Administration (NMPA), including Satri-cel, the world's first regulatory approval of a CAR-T cell therapy for a solid tumor.

Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India's Central Drugs Standard Control Organisation (CDSCO). Rounding out the global landscape, South Korea's Ministry of Food and Drug Safety (MFDS) approved the country's first domestically developed CAR-T therapy, RIMQARTO, marking the entry of a new regulatory market into the commercial CAR-T landscape.

CAR-T Market Expansion and Industry Growth

These regulatory approvals mark a major milestone, solidifying the CAR-T market as a dominant force in biotech. Mergers and acquisitions have only accelerated, demonstrating strong and growing investor confidence. The industry's formative deals, including Celgene's acquisition of Juno Therapeutics for $9 billion, Bristol-Myers Squibb's subsequent acquisition of Celgene for $74 billion, Gilead's acquisition of Kite Pharma for $11.9 billion, and Astellas Pharma's purchase of Xyphos Biosciences for $665 million, established CAR-T as a must-own capability for large pharma.

That appetite hasn't slowed. Since 2024 alone, the industry has recorded over $8 billion in additional licensing deals and acquisitions, including AbbVie's acquisition of Capstan Therapeutics, Roche's acquisition of Poseida Therapeutics, and Bristol Myers Squibb's acquisition of Orbital Therapeutics, as pharmaceutical giants race to secure next-generation platform technologies. These transactions highlight the increasing commitment from major pharmaceutical companies to invest in CAR-T technologies and shape the future of cancer treatment.

As CAR-T therapy continues to evolve, the industry faces key challenges, including improving gene-transfer efficiency and mitigating toxicity risks. Researchers are actively exploring CRISPR and electroporation technologies to enhance T-cell modification, while others develop "on-off" switches to regulate CAR-T activity.

One of the biggest hurdles has long been the treatment of solid tumors, as clinical trials have shown lower response rates compared to blood cancers. This is changing: nearly 290 registered clinical trials are now targeting solid tumors, and China's approval of Satri-cel proves the barrier is no longer insurmountable. A major focus remains on identifying solid tumor-specific antigens to further improve efficacy in these cancers.

Beyond oncology, the industry is making an aggressive push into autoimmune disease. Over 250 active clinical trials are now exploring CAR-T's potential to treat conditions like systemic lupus erythematosus (SLE), systemic sclerosis, and multiple sclerosis, with early data showing drug-free remissions in some patients.

Currently, the marketed CAR-T therapy landscape and the large majority of ongoing clinical trials rely on autologous (patient-derived) cells. However, the next breakthrough lies in allogeneic CAR-T therapies, which are off-the-shelf solutions that could streamline manufacturing, reduce costs, and expand patient accessibility.

Global CAR-T Cell Therapy Market

The CAR-T cell therapy market has grown from early experimental treatments to a multi-billion-dollar industry with global reach. Early successes in blood cancers have paved the way for broader applications, with companies ranging from startups to biotech giants working to expand the field. As innovation continues, the future of CAR-T therapy holds immense potential to revolutionize cancer treatment worldwide.

This report provides the following insights:

• A brief history of CAR-T therapy, highlighting its evolution from 1989 to the present, its transformative potential, and the accelerating activities within the CAR-T sector.
• An examination of the manufacturing process and the costs associated with developing autologous and allogeneic CAR-T cell therapies.
• An overview of cancer biomarkers or antigens targeted by CAR-T cells.
• A detailed analysis of the global CAR-T patent landscape, including leading sponsors, inventors, and regions.
• An in-depth look at the rates, types, and trends for clinical trials involving CAR-T cells, including its rapidly emerging role in autoimmune disease.
• A review of the rates and types of CAR-T cell therapy scientific publications.
• An overview of NIH grants awarded to support CAR-T cell therapy research.
• A review of industry dealmaking and strategic partnerships within the CAR-T sector.
• Descriptions of all 16 globally approved CAR-T therapies, including Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, Aucatzyl, Carteyva, Yikaida, Zevor-cel, Yorwida, Fucaso, Satri-cel, NexCAR19, Qartemi, and RIMQARTO.
• A review of reimbursement policies for CAR-T therapies in the U.S. and outcome-based reimbursement policies in Europe.
• A global market analysis for CAR-T cell therapies by Geography, Product, and Indication.
• Profiles of over 170 leading CAR-T cell therapy market competitors, including their novel products, emerging candidates, and proprietary technology platforms.
• And so much more.

Key Questions Answered in This Report:

• What are the features of the FDA-approved CAR-T therapies that are currently available, who is manufacturing them, and who is commercializing them?
• What future developments are expected within the CAR-T sector?
• Which new CAR-T products are anticipated to enter the market soon?
• How many automated manufacturing systems are available for CAR-T production?
• Which antigens are most commonly targeted in liquid and solid cancers?
• What is the number of CAR-T-related patent publications and granted patents from 2012 to present?
• Which countries hold the most CAR-T patents?
• Which companies have filed the most CAR-T patents?
• Who are the top CAR-T patent inventors?
• How many CAR-T-related clinical trials have been registered from 2003 to the present?
• Which biomarker antigens dominate the CAR-T clinical trial landscape?
• How many CAR-T deals were signed in the past two years and who entered into them?
• What is the current market size for globally approved CAR-T therapies?
• What promising CAR-T candidates are expected to reach commercialization soon?
• How are CAR-T therapies reimbursed in the U.S. and Europe?
• What is the market size for CAR-T therapies by geography, product, and indication?
• Which major companies are developing CAR-T cell therapies?
• And so much more.

This global strategic report will position you to:

• Capitalize on rapidly emerging trends
• Optimize decision-making
• Reduce company risk
• Approach partners/investors for collaboration or funding
• Implement an informed and advantageous business strategy through 2035 and beyond

With the competitive nature of this global market, you don't have the time to do the research. Claim this report to become immediately informed, without missing critical opportunities.

Companies and Organizations Mentioned

Novartis, Gilead Sciences, Kite Pharma, Bristol Myers Squibb, 2seventy bio, Legend Biotech, Janssen Pharmaceuticals, Autolus Therapeutics, JW Therapeutics, Fosun Pharma, CARsgen Therapeutics, IASO Biotherapeutics, Immuneel Therapeutics, ImmunoACT, Curocell, AbbVie, AstraZeneca, Roche Group, Eli Lilly, Regeneron, Genentech, BioNTech, Sana Biotechnology, Arcellx, Allogene Therapeutics, Caribou Biosciences, CRISPR Therapeutics, Intellia Therapeutics, Precision Biosciences, Century Therapeutics, Fate Therapeutics, Beam Therapeutics, Editas Medicine, Cartesian Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Capstan Therapeutics, Orbital Therapeutics, Umoja Biopharma, Lyell Immunopharma, Mustang Bio, Vor Biopharma, Gracell Biotechnologies, Poseida Therapeutics, Adicet Bio, Atara Biotherapeutics, Cellectis, Celyad Oncology, Wugen, Strand Therapeutics, Waypoint Bio, Kelonia Therapeutics, ArsenalBio, Anixa Biosciences, Xyphos Biosciences, Antion Biosciences, Miltenyi Biomedicine, MaxCyte, Thermo Fisher Scientific, Terumo BCT, and 112 more.

About the Publisher

Founded in 2006, the publisher is the world’s first and only market research firm to specialize in the stem cell industry. Headquartered near Washington, DC, to be situated near the U.S. FDA, NIH, and Capitol Hill, it has been tracking this market for 20+ years, developing proprietary datasets, extracting trend data, and conducting industry interviews to which AI doesn't have access.

To date, the publisher’s research has been cited by the Wall Street Journal, AABB, and Vogue Magazine, as well as quoted by Tony Robbins in his best-selling book, LifeForce. Today, the publisher operates the world's largest stem cell industry news site, attracting nearly a million readers per year.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, it is your global leader in stem cell and cell therapy industry data.

1. REPORT OVERVIEW

• 1.1 Statement of the Report
• 1.2 Executive Summary
• 1.3 Introduction

2. CAR-T CELL THERAPY & CAR-T TECHNOLOGIES

• 2.1 Structure of a CAR-T Cell
• 2.2 Engineering of T Cells into CAR-T Cells
• 2.3 The Five Generations of CAR-Ts
  • 2.3.1 1st Generation CAR-T
  • 2.3.2 2nd Generation CAR-T
  • 2.3.3 3rd Generation CAR-T
  • 2.3.4 4th Generation CAR-T
  • 2.3.5 5th Generation CAR-T
• 2.4 Emerging CAR-T Technologies
  • 2.4.1 In Vivo CAR-T Cell Therapy
  • 2.4.2 Off-the-Shelf (Allogeneic) CAR-T Cells
  • 2.4.3 Armored CAR-Ts
  • 2.4.4 Logic-Gated CAR-T Cells

3. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2026

• 3.1 Fifteen Milestones that Shaped the CAR-T Revolution
  • 3.1.1 First CAR Prototype (1993)
  • 3.1.2 Second-Generation CAR Invention (1998)
  • 3.1.3 CD19 Target Defined (2002)
  • 3.1.4 First Adult CLL Remission (2010)
  • 3.1.5 Emily Whitehead Breakthrough (2012)
  • 3.1.6 First FDA Breakthrough Designation (2014)
  • 3.1.7 Historical First FDA Approval (2017)
  • 3.1.8 Solidifying Adult Lymphoma Market (2017)
  • 3.1.9 First Mantle Cell Lymphoma Approval (2020)
  • 3.1.10 Entering Multiple Myeloma (2021)
  • 3.1.11 Expansion into Autoimmune Diseases (2022)
  • 3.1.12 Solid Tumor Breakthroughs (2023)
  • 3.1.13 Allogeneic "Off-the-Shelf" Validation (2024)
  • 3.1.14 Point-of-Care (Hospital Bedside) Manufacturing (2025)
  • 3.1.15 In Vivo mRNA Platforms (2026)

4. SCALABLE MANUFACTURING OF CAR-T CELL THERAPIES

• 4.1 Scalability Models
  • 4.1.1 Scale-Out Model (Autologous)
    • 4.1.1.1 Core Mechanics of the Scale-Out Model
    • 4.1.1.2 Centralized Scale-Out Model
    • 4.1.1.3 Decentralized Scale-Out Model
    • 4.1.1.4 The End-to-End Scale-Out Workflow
  • 4.1.2 Scale-Up Model (Allogeneic)
    • 4.1.2.1 Core Workflow of Allogeneic Scale-Up
• 4.2 Currently Used CAR-T Manufacturing Platforms
  • 4.2.1 All-in-One Integrated Instruments
  • 4.2.2 The Market Leader in All-in-One Integrated Platforms
    • 4.2.2.1 CliniMACS’ Closest Competitor
  • 4.2.3 Modular & Specialized Expansion Bioreactors
    • 4.2.3.1 Largest-Selling Modular & Specialized Expansion Bioreactors
      • 4.2.3.1.1 The Static Leader: Wilson Wolf G-Rex Platform
      • 4.2.3.1.2 The Dynamic Leader: Cytiva Xuri W25 Cell Expansion System
• 4.3 Cost of Manufacturing Autologous CAR-T Cell Therapies
  • 4.3.1 Emerging Models Altering the Cost Landscape
• 4.4 Cost of Manufacturing Allogeneic CAR-T Cell Therapies

5. CAR-T PATENT LANDSCAPE

• 5.1 Cost of Filing and Securing a CAR-T Therapy Patent
  • 5.1.1 Licensing Cost of CAR-T Cell Therapy Patents
    • 5.1.1.1 Top 10 CAR-T Cell Therapy Licensing Deals
• 5.2 Number of CAR-T Cell Therapy Patent Filings, 2000 to
  • 5.2.1 Patent Filings for Autologous & Allogeneic CAR-T Therapies Compared
  • 5.2.2 Patent Filings by CAR-T Generation Type
  • 5.2.3 Patent Filings for Blood Cancers & Solid Tumors Compared, 2015-2025
  • 5.2.4 CAR-T Patent Filings for Autoimmune Diseases
  • 5.2.5 Patent Filings for In Vivo CAR-T Cell Therapies
• 5.3 Distribution of Filed CAR-T Patents by Jurisdiction
  • 5.3.1 Top 20 CAR-T Cell Therapy Jurisdictions
• 5.4 Top 20 CAR-T Cell Therapy Patent Applicants
• 5.5 Top 20 CAR-T Cell Therapy Patent Inventors
• 5.6 Top 20 CAR-T Cell Therapy Patent Owners
• 5.7 Legal Status of CAR-T Cell Therapy Filed Patents
  • 5.7.1 Macro Global Patent Portfolio Distribution
• 5.8 Top 20 Granted CAR-T Cell Therapy Patents

6. EVOLVING LANDSCAPES IN CAR-T RESEARCH

• 6.1 The Bedrock Ascent of CAR-T Research Publications
• 6.2 The Allogeneic Ascent over Autologous CAR-T PubMed.gov Publications
• 6.3 The Solid Tumor Breakthrough in CAR-T Research Publications
• 6.4 PubMed Papers on CAR-T In Situ Revolution
• 6.5 CAR-T’s Next Frontier in Refractory Autoimmune Remission
  • 6.5.1 Mechanism of Action & Immune Reset
  • 6.5.2 Top Clinical Indications & Successes

7. THE EXPANDING MAP OF CAR-T CLINICAL TRIALS

• 7.1 Recent Trends in CAR-T Cell Therapy Clinical Trials
• 7.2 Clinical Trial Cost to Advance a Single CAR-T Cell Therapy Candidate
• 7.3 Percent Share of CAR-T Clinical Trials by CAR Generation Type
• 7.4 Percent Share of CAR-T Clinical Trials by Co-stimulatory Domains
• 7.5 Percent Share of CAR-T Clinical Trials by Target Disease
• 7.6 CAR-T Clinical Trials by Sponsor Type
• 7.7 Percent Share of Top 5 Hospitals & Clinical Centers in CAR-T Clinical Trials
• 7.8 Percent Share of Top 7 Companies in CAR-T Clinical Trials
• 7.9 Percent Share of CAR-T Clinical Trials by Top 7 Academic Institutions
• 7.10 CAR-T Clinical Trials’ Study Phases
• 7.11 Funders of CAR-T Clinical Trials

8. CAR-T FUNDING LANDSCAPE

• 8.1 Venture Capital Funding in CAR-T Sector, 2024-2026
  • 8.1.1 Legend Biotech
  • 8.1.2 Waypoint Bio
  • 8.1.3 CREATE Medicines, Inc.
  • 8.1.4 Orca Bio
  • 8.1.5 Orum Therapeutics
  • 8.1.6 Syneron Bio
  • 8.1.7 Link Cell Therapies
  • 8.1.8 MagicRNA Biotech
  • 8.1.9 Wugen
  • 8.1.10 Innovacell
  • 8.1.11 Anocca
  • 8.1.12 Strand Therapeutics
  • 8.1.13 ArsenalBio
  • 8.1.14 Capstan Therapeutics
  • 8.1.15 YolTech Therapeutics
• 8.2 CAR-T Collaboration Deals, 2023- July,
  • 8.2.1 Johnson & Johnson/Sail Biomedicines
  • 8.2.2 Circio Holding ASA & Tcelltech GmbH
  • 8.2.3 Helix Cell Therapeutics & Biocell Innovations
  • 8.2.4 Applied Cells, Inc. & Immuneel Therapeutics
  • 8.2.5 Dispatch Bio & CARsgen Therapeutics
  • 8.2.6 Cellares & University of Wisconsin School of Medicine
  • 8.2.7 A-SEEDS, Co., Ltd. & Cell Therapies Pty Ltd.
  • 8.2.8 Kytopen Corporation & Excellos, Inc.
  • 8.2.9 Kelonia Therapeutics & Janssen Biotech, Inc.
  • 8.2.10 Gilead's Kite Pharma & Pregene Biopharma
  • 8.2.11 Gilead's Kite Pharma & Interius BioTherapeutics
  • 8.2.12 Proton Advanced Solutions & EVA Pharma
  • 8.2.13 Vector BioMed & Muni Seva Ashram
  • 8.2.14 Gilead's Kite Pharma & Arcellx
  • 8.2.15 Caring Cross & ImmunoACT
  • 8.2.16 Bristol Myers Squibb & Cellares
  • 8.2.17 Gilead Sciences (Kite) & Arcellx
  • 8.2.18 ImmunoACT, IIT Bombay, & Tata Memorial Centre
  • 8.2.19 Janssen Biotech & Cellular Biomedicine Group
  • 8.2.20 Johnson & Johnson and Novartis
• 8.3 Merger & Acquisition Deals in CAR-T Therapy Sector
  • 8.3.1 Merger & Acquisition in
    • 8.3.1.1 Johnson & Johnson Acquires Sail Biomedicines
    • 8.3.1.2 Liminatus Pharma Acquires InnocsAI LLC
    • 8.3.1.3 Gilead Sciences, Inc. Acquires Arcellx, Inc.
    • 8.3.1.4 Eli Lilly Acquires Kelonia Therapeutics
    • 8.3.1.5 Eli Lilly Acquires Orna Therapeutics
    • 8.3.1.6 Bristol Myers Squibb Acquires Orbital Therapeutics
    • 8.3.1.7 AbbVie Acquires Capstan Therapeutics
    • 8.3.1.8 AstraZeneca Acquires Esco Biotec
    • 8.3.1.9 Roche Acquires Poseida Therapeutics
    • 8.3.1.10 AstraZeneca Acquires Gracell Biotechnologies
• 8.4 IPO Funding Raised by CAR-T Companies in Recent Years
  • 8.4.1 Legend Biotech
  • 8.4.2 Cabaletta Bio
  • 8.4.3 Editas Medicine
  • 8.4.4 Allogene Therapeutics
  • 8.4.5 Artiva Biotherapeutics
  • 8.4.6 Autolus Therapeutics
  • 8.4.7 Kyverna Therapeutics

9. GLOBALLY APPROVED CAR-T CELL THERAPIES

• 9.1 Kymriah (tisagenlecleucel)
  • 9.1.1 Product Description
  • 9.1.2 Foundational Technology
    • 9.1.2.1 Patent Protection
  • 9.1.3 Indications Approved for Kymriah
    • 9.1.3.1 Dates of Approvals for Different Indications
  • 9.1.4 Marketing Status
  • 9.1.5 Development Timeline for Kymriah
  • 9.1.6 Manufacturing of Kymriah
    • 9.1.6.1 Manufacturing Locations
  • 9.1.7 Certified Kymriah Treatment Centers
  • 9.1.8 Cost of Treatment
    • 9.1.8.1 Estimated Out-of-Pocket Costs & Regional Variations
  • 9.1.9 Competing Therapies with Kymriah
  • 9.1.10 Revenue Generation by Kymriah
• 9.2 Yescarta (axicabtagene ciloleucel)
  • 9.2.1 Product Description
  • 9.2.2 Foundational Technology
    • 9.2.2.1 Patent Protection
  • 9.2.3 Indications Approved for Yescarta
  • 9.2.4 Approval of Yescarta in Different Countries
  • 9.2.5 Development Timeline of Yescarta
  • 9.2.6 Manufacturing Process
    • 9.2.6.1 Manufacturing Locations
  • 9.2.7 Treatment Centers
  • 9.2.8 Treatment Cost
  • 9.2.9 Competing Therapies
  • 9.2.10 Revenue Generation
• 9.3 Tecartus (brexucabtagene autoleucel)
  • 9.3.1 Product Description
  • 9.3.2 Foundational Technology & Patent Protection
  • 9.3.3 Indications Approved for Tecartus
  • 9.3.4 Dates of Approvals
  • 9.3.5 Development Timeline
  • 9.3.6 Manufacturing Process
    • 9.3.6.1 Manufacturing Location
  • 9.3.7 Cost of Treatment
  • 9.3.8 Competing Therapies
  • 9.3.9 Revenue Generation
• 9.4 Breyanzi (lisocabtagene maraleucel)
  • 9.4.1 Product Description
  • 9.4.2 Foundational Technology
    • 9.4.2.1 Patent Protection
  • 9.4.3 Approved Indications for Breyanzi
  • 9.4.4 Dates of Approval by Country/Region
  • 9.4.5 Development Timeline
  • 9.4.6 Manufacturing Process
    • 9.4.6.1 Manufacturing Locations
  • 9.4.7 Authorized Treatment Centers
    • 9.4.7.1 Cost of Treatment
  • 9.4.8 Competing Therapies
  • 9.4.9 Revenue Generation
• 9.5 Abecma (idecabtagene vicleucel)
  • 9.5.1 Product Description
  • 9.5.2 Foundational Technology
  • 9.5.3 Patent Protection
  • 9.5.4 Approved Indications
  • 9.5.5 Dates of Approval
  • 9.5.6 Development Timeline
  • 9.5.7 Manufacturing Process
    • 9.5.7.1 Manufacturing Location
  • 9.5.8 Certified Treatment Centers
  • 9.5.9 Treatment Cost
  • 9.5.10 Competing Therapies
  • 9.5.11 Revenue Generation
• 9.6 Carvykti (ciltacabtagene autoleucel)
  • 9.6.1 Product Description
  • 9.6.2 Foundational Technology
    • 9.6.2.1 Patent Protection
  • 9.6.3 Approved Indications
  • 9.6.4 Dates of Approval
  • 9.6.5 Development Timeline of Carvykti
    • 9.6.6.1 Manufacturing Locations
  • 9.6.7 Certified Treatment Centers
  • 9.6.8 Cost of Treatment
  • 9.6.9 Competing Therapies
  • 9.6.10 Revenue Generation
• 9.7 Aucatzyl (obecabtagene autoleucel)
  • 9.7.1 Product Description
  • 9.7.2 Foundational Technology
    • 9.7.2.1 Patent Protection
  • 9.7.3 Approved Indications
  • 9.7.3 Dates of Approval
  • 9.7.4 Marketing Status
  • 9.7.5 Development Timeline
  • 9.7.6 Manufacturing
  • 9.7.7 Manufacturing Location
  • 9.7.8 Cost of Treatment
  • 9.7.9 Other Competing Therapies
  • 9.7.10 Revenue Generation
• 9.8 Carteyva (relmacabtagene autoleucel)
  • 9.8.1 Product Description
  • 9.8.2 Foundational Technology
  • 9.8.3 Approved Indications
  • 9.8.4 Dates of Approval
  • 9.8.5 Marketing Status
  • 9.8.6 Development Timeline
  • 9.8.7 Manufacture
  • 9.8.8 Manufacturing Location
  • 9.8.9 Cost of Treatment
  • 9.8.10 Competing Therapies
  • 9.8.11 Revenue Generation
• 9.9 Yikaida (axicabtagene ciloleucel)
  • 9.9.1 Product Description
  • 9.9.2 Foundational Technology
    • 9.9.2.1 Patent Protection
  • 9.9.3 Approved Indications
  • 9.9.4 Dates of Approval
  • 9.9.5 Marketing Status
  • 9.9.6 Development Timeline
  • 9.9.7 Manufacturing Process
    • 9.9.7.1 Manufacturing Location
  • 9.9.8 Certified Treatment Centers
  • 9.9.9 Cost of Treatment
  • 9.9.10 Approved Competing Therapies
  • 9.9.11 Revenue Generation
• 9.10 Zevor-cel (Zevorcabtagene Autoleucel)
  • 9.10.1 Product Description
  • 9.10.2 Foundational Technology
  • 9.10.3 Approved Indications
  • 9.10.4 Approval Date
  • 9.10.5 Development Timeline
  • 9.10.6 Manufacturing
    • 9.10.6.1 Manufacturing Locations
  • 9.10.7 Certified Treatment Centers
  • 9.10.8 Cost of Treatment
  • 9.10.9 Approved Competing Therapies
  • 9.10.10 Revenue Generation
• 9.11 Yorwida (inaticabtagene autoleucel)
  • 9.11.1 Product Description
  • 9.11.2 Foundational Technology
  • 9.11.3 Approved Indications
  • 9.11.4 Dates of Approval
  • 9.11.5 Marketing Status
  • 9.11.6 Development Timeline
  • 9.11.7 Manufacturing
    • 9.11.7.1 Manufacturing Location
  • 9.11.8 Authorized Treatment Centers
  • 9.11.9 Cost of Treatment
  • 9.11.10 Approved Competing Therapies
• 9.12 Fucaso (equecabtagene autoleucel)
  • 9.12.1 Product Description
  • 9.12.2 Foundational Technology
    • 9.12.2.1 Patent Protection
  • 9.12.3 Approved Indications
  • 9.12.4 Dates of Approval
  • 9.12.5 Marketing Status
  • 9.12.6 Development Timeline
  • 9.12.7 Manufacturing
    • 9.12.7.1 Manufacturing Locations
  • 9.12.8 Cost of Treatment
  • 9.12.9 Competing Approved Therapies
• 9.13 Satri-cel (Satricabtagene Autoleucel)
  • 9.13.1 Product Description
  • 9.13.2 Approved Indications
  • 9.13.3 Date of Approval
  • 9.13.4 Marketing Status
  • 9.13.5 Development Timeline
  • 9.13.6 Manufacturing Process
    • 9.13.6.1 Manufacturing Location
  • 9.13.7 Certified Treatment Centers
  • 9.13.8 Cost of Treatment
  • 9.13.9 Approved Competing Therapies
• 9.14 Qartemi (varnimcabtagene autoleucel)
  • 9.14.1 Product Description
  • 9.14.2 Foundational Technology
  • 9.14.3 Approved Indications
  • 9.14.4 Dates of Approval
  • 9.14.5 Marketing Status
  • 9.14.6 Development Timeline
  • 9.14.7 Manufacturing
    • 9.14.7.1 Manufacturing Location
  • 9.14.8 Certified Treatment Centers
  • 9.14.9 Cost of Treatment
  • 9.14.10 Approved CAR-T & Non-CAR-T Competing Therapies
  • 9.14.11 Revenue Generation
• 9.15 NexCAR19 (talicabtagene autoleucel)
  • 9.15.1 Product Description
  • 9.15.2 Foundational Technology
  • 9.15.3 Approved Indications
  • 9.15.4 Date of Approval
  • 9.15.5 Marketing Status
  • 9.15.6 Development Timeline
  • 9.15.7 Manufacturing
    • 9.15.7.1 Manufacturing Location
  • 9.15.9 Certified Treatment Centers
• 9.16 RIMQARTO® (anbalcabtagene autoleucel)
  • 9.16.1 Product Description
  • 9.16.2 Foundational Technology
  • 9.16.3 Approved Indications
  • 9.16.4 Date of Approval
  • 9.16.5 Marketing Status
  • 9.16.6 Development Timeline
  • 9.16.7 Manufacturing
    • 9.16.7.1 Manufacturing Location

10. MOST ANTICIPATED CAR-T APPROVALS BETWEEN 2026 AND 2036

• 10.1 Yescarta as Frontline CAR-T Cell Therapy
• 10.2 Breyanzi as Frontline CAR-T Cell Therapy
• 10.3 KYV-101 for Autoimmune Diseases
• 10.4 Dual-Targeting Standard (CD19/CD20 CAR-Ts)
  • 10.4.1 Dual-Targeting JNJ-4496
  • 10.4.2 Dual-Targeting KITE-363
• 10.5 ALLO-501A/Cema-cel (Allogeneic "Off-the-Shelf")
• 10.6 CTX112 Next-Gen CRISPR-Edited CAR-T
• 10.7 JV-394 CAR-T Targeting CD7/CD5/CD94
• 10.8 KIR-CAR-T Cell Therapies for Solid Tumors
• 10.9 FT819 iPSC-Derived Cellular Therapy
  • 10.9.1 Key Engineering Modifications in FT819
  • 10.9.2 Clinical Milestones & Trial Updates for FT819
• 10.10 In Vivo CAR-T Therapeutics (The "No-Lab" Alternative)
  • 10.10.1 Cutting-Edge In Vivo CAR-T Candidates in Clinical Trials
    • 10.10.1.1 KLN-1010 (inMMyCAR Trial)
    • 10.10.1.2 INT2104
    • 10.10.1.3 ORN-252/Orna Therapeutics
• 10.11 CAR-Ts targeting Fibrosis and Senescence
• 10.12 UCARTFAP
• 10.13 FAP-Targeted In Vivo mRNA-LNP

11. CAR-T UTILIZATION, COST OF DEVELOPMENT AND TREATMENT

• 11.1 Utilization in the U.S.
• 11.2 Utilization in Europe
• 11.3 Utilization in Asia/Pacific
• 11.4 Medical Tourism in the Context of CAR-T Treatment
  • 11.4.1 Top Global Hubs for CAR-T Medical Tourism
    • 11.4.1.1 Value of CAR-T Treatment through Medical Tourism
    • 11.4.1.2 Hidden Costs and “Total Budget” Math for Travelers
  • 11.4.2 Two Prominent Destinations for International Patients
    • 11.4.2.1 Turkey
      • 11.4.2.1.1 Top Hospitals & Accreditations in Turkey
    • 11.4.2.2 India
      • 11.4.2.2.1 Patient Demographics by Region
      • 11.4.2.2.2 Key Indian Centers Accommodating Foreign Patients
• 11.5 Manufacturing Cost of CAR-T Cell Therapy
  • 11.5.1 Cost of Developing CAR-T Therapy from Discovery to Marketing Approval
  • 11.5.2 Cost of Developing CAR-T Therapy from Academics to Spinouts
• 11.6 Cost of CAR-T Treatments across Geographies
  • 11.6.1 Total Treatment Cost for CAR-T Cell Therapies in the United States
  • 11.6.2 Total CAR-T Treatment Cost in Europe
  • 11.6.3 Total CAR-T Treatment Cost in Japan
  • 11.6.4 Total CAR-T Treatment Cost in South Korea
  • 11.6.5 Total CAR-T Treatment Cost in Australia
  • 11.6.6 Total CAR-T Treatment Cost in China
  • 11.6.7 Total CAR-T Treatment Cost in India

12. DISEASES TREATED WITH CAR-T CELL THERAPIES

• 12.1 Blood Cancers
  • 12.1.1 Acute Lymphoblastic Leukemia (ALL)
  • 12.1.2 B-Cell Lymphomas
  • 12.1.3 Multiple Myeloma
• 12.2 Autoimmune diseases
  • 12.2.1 Systemic Lupus Erythematosus (SLE)
    • 12.2.1.1 CAR-T Development for SLE
  • 12.2.2 Multiple Sclerosis (MS)
  • 12.2.3 Pemphigus Vulgaris (PV)
    • 12.2.3.1 Development of CAR-T for PV
  • 12.2.4 Systemic Sclerosis (SSc)
    • 12.2.4.1 CAR-T Development for SSc
      • 12.2.4.1.1 Prominent CAR-T Clinical Trial Candidates for SSc
• 12.3 Solid Tumors
  • 12.3.1 Gastrointestinal & Abdominal Cancers
  • 12.3.2 Brain & Central Nervous System (CNS) Tumors
  • 12.3.3 Lung and Thoracic Cancers
  • 12.3.4 Pediatric and Musculoskeletal Cancers
• 12.4 Infectious and Senescence-Associated Diseases
  • 12.4.1 CAR-T Applications in Infectious Diseases
  • 12.4.2 CAR-T Applications in Senescence-Associated Diseases
• 12.5 The Clinical Superiority of CAR-T Cell Therapy over Non-CAR-T Therapies
  • 12.5.1 "Living Drug" Dynamics (Long-Term Vigilance)
  • 12.5.2 MHC-Independent Target Recognition
  • 12.5.3 Laser-Focused Specificity
  • 12.5.4 Single Infusion vs. Continuous Treatment Cycles

13. MARKET ANALYSIS

• 13.1 Global Market for CAR-T Cell Therapy Products
  • 13.1.1 Sales of FDA-Approved CAR-T Cell Therapy Products between 2017 and
  • 13.1.2 Sales History of CAR-T Cell Therapies Approved in China
  • 13.1.3 Sales History of Approved CAR-T Cell Therapies in India
  • 13.1.4 RIMQARTO: The South Korean Approved CAR-T
    • 13.1.4.1 The Reimbursement Gateway (The Ultimate Sales Driver)
    • 13.1.4.2 Pricing and Cost Competitiveness
    • 13.1.4.3 Clinical Edge Driving Market Capture
• 13.2 Estimated Global Market for CAR-T Cell Therapies, 2025-2035
  • 13.2.1 Global CAR-T Cell Therapy Market by Targeted Antigens, 2017-2025
  • 13.2.2 Estimated Global Market for CAR-T Therapies by Target Antigen, 2025-2035
• 13.3 Global CAR-T Market by Indication
  • 13.3.1 The Percent Share of CAR-T Market by Approved Indications
    • 13.3.1.1 Global CAR-T Market by Lymphoma Sub-Type
    • 13.3.1.2 CAR-T Market for Multiple Myeloma by Sub-Type
  • 13.3.2 CAR-T Market for Leukemia Indications
  • 13.3.3 CAR-T for Solid Tumor Indications

14. CATEGORIES OF CAR-T COMPANIES

• 14.1 Key CAR-T Companies by Generation and Signaling
• 14.2 Next-Generation CAR-Ts
  • 14.2.1 Comparison of Second Generation & Next-Generation CAR-Ts
• 14.3 CAR-T Companies by Cellular Source (Autologous vs. Allogeneic)
• 14.4 CAR-T Companies by Gene Editing/Modification Technology
• 14.5 CAR-T Companies by Targeting and Logic Gate Technology
• 14.6 CAR-T Companies by Indication Specialization
• 14.7 CAR-T Companies by Production model
• 14.8 Percent Shares of Autologous & Allogeneic CAR-T Companies
• 14.9 Percent Share of CAR-T Companies by Generation Types

15. COMPANY PROFILES

• 15.1 4immune Therapeutics
  • 15.1.1 CAL/CAR-T Cell Therapy Platform
• 15.2 A2 Biotherapeutics, Inc.
  • 15.2.1 Tmod™
  • 15.2.2 A2 Biotherapeutics’ RD Pipeline
• 15.3 AAX Biotech AB
  • 15.3.1 Seqitope®
  • 15.3.2 Opti-mAb®
• 15.4 AbbVie
  • 15.4.1 Key CAR-T Programs & Partnerships
• 15.5 AbClon
  • 15.5.1 NEST Platform
  • 15.5.2 zCAR-T Platform
  • 15.5.3 AbClon’s CAR-T Product Candidates
• 15.6 AbelZeta Pharma
  • 15.6.1 RMAT designation for C-CAR168
  • 15.6.2 Armored CAR-T Technology
  • 15.6.3 GPC3-Targeting CAR-T (C-CAR031)
• 15.7 Adicet Bio
  • 15.7.1 Leading Clinical Candidates
• 15.8 Alaya.bio
  • 15.8.1 Core Technology
  • 15.8.2 Partnerships & Milestones
• 15.9 Aleta Biotherapeutics
  • 15.9.1 CAR-T Engagers (CTEs)
• 15.10 Allogene Therapeutics
  • 15.10.1 AlloCAR T™ Platform
  • 15.10.2 Dagger™ Technology
  • 15.10.3 TurboCAR™ technology
  • 15.10.4 ALLO-647 (Lymphodepletion)
  • 15.10.5 Cloak™ Technology
• 15.11 Allogenica
  • 15.11.1 Pre-T Cell Technology
  • 15.11.2 AlloCAR T™
• 15.12 AlloTera Therapeutics
  • 15.12.1 Core Technology & Pipeline
• 15.13 Alpha Biopharma
  • 15.13.1 CAR-T Cell Therapy Context & Pipeline
• 15.14 Angeles Therapeutics
  • 15.14.1 Synthetic Immune Receptor-T (SIR-T™) platform
• 15.15 Anixa Biosciences
  • 15.15.1 CAR-T Program
• 15.16 Antion Biosciences SA
  • 15.16.1 Core CAR-T Technologies
  • 15.16.2 Key CAR-T Pipeline Programs
  • 15.16.3 Strategic Partnerships
• 15.17 Arbele Limited
  • 15.17.1 Arbele's CAR-T and Immuno-Oncology Approach
• 15.18 Arcellx, Inc.
  • 15.18.1 Lead Therapy (Anito-cel)
  • 15.18.2 ARC-SparX platform
  • 15.18.3 Acquisition by Gilead Sciences
• 15.19 ArsenalBio
  • 15.19.1 CITE Platform
  • 15.19.2 Key Pipeline Programs
• 15.20 A-SEEDS Co., Ltd.
  • 15.20.1 Core Focus & Business Operations
• 15.21 AstraZeneca
  • 15.21.1 Key CAR-T Assets & Strategy
  • 15.21.2 Disruptive "In Vivo" Technology
  • 15.21.3 Expansion beyond Oncology
• 15.22 Atara Biotherapeutics
  • 15.22.1 Allogeneic EBV T-Cell Platform
• 15.23 Autolus Therapeutics
  • 15.23.1 Modular CAR T-Cell Engineering
  • 15.23.2 Fast Off-Rate Binding CARs
  • 15.23.3 R&D Pipeline
• 15.24 AvenCell Therapeutics, Inc.
  • 15.24.1 Universal Switchable CAR Platform (UniCAR/RevCAR)
  • 15.24.2 UniCAR
  • 15.24.3 RevCAR
  • 15.24.4 R&D Pipeline
• 15.25 Beam Therapeutics
  • 15.25.1 Multiplex Base Editing
  • 15.25.2 BEAM-201
• 15.26 BeiCell Therapeutics
  • 15.26.1 Technology: The CiPSC Platform
  • 15.26.2 Approaches to CAR-T Cell Therapy
• 15.27 Bio4t2
  • 15.27.1 PrismCore™
  • 15.27.2 Bio-Strike™
• 15.28 BioNTech SE
  • 15.28.1 CARVac
  • 15.28.2 Product Candidates
    • 15.28.2.1 BNT211 (CLDN6 CAR-T + CARVac)
    • 15.28.2.2 BNT314/GEN1059
• 15.29 BrainChild Bio
  • 15.29.1 Multiplex Targeting
  • 15.29.2 BCB-276: The Lead Candidate
• 15.30 Bristol Myers Squibb
  • 15.30.1 Approved CAR-T Products
    • 15.30.1.1 Breyanzi (lisocabtagene maraleucel)
    • 15.30.1.2 Abecma (idecabtagene vicleucel)
  • 15.30.2 Product Candidates in ongoing Clinical Trials
• 15.31 BioAgilytix
  • 15.31.1 Key Services for CAR-T Development
• 15.32 BioOra
  • 15.32.1 Atla-cel (WZTL-002)
• 15.33 Biosceptre International Limited
  • 15.33.1 BRiDGECAR™
  • 15.33.2 R&D Pipeline
• 15.34 Cabaletta Bio
  • 15.34.1 CARTA (Chimeric Antigen Receptor T cells for Autoimmunity)
  • 15.34.2 CAAR T (Chimeric Autoantibody Receptor T cells)
  • 15.34.3 R&D Programs
• 15.35 Capstan Therapeutics
  • 15.35.1 Core Technology
  • 15.35.2 Pipeline & Focus Areas
• 15.36 Caravan Biologix
  • 15.36.1 Mini-CAR™ Technology
  • 15.36.2 Mini-VAN™ Technology
• 15.37 CARBio Therapeutics
  • 15.37.1 Core Focus & Pipeline
• 15.38 Caribou Biosciences
  • 15.38.1 chRDNA (CRISPR hybrid RNA-DNA)
  • 15.38.2 Caribou’s Clinical Programs
• 15.39 Carina Biotech
• 15.40 Caring Cross
  • 15.40.1 Core Mission & Approach
  • 15.40.2 Key Therapeutic Pipelines
  • 15.40.3 Global Collaborations
• 15.41 Caris Life Sciences
  • 15.41.1 ADAPT™ Platform
  • 15.41.2 CODEai™ Data Platform
• 15.42 CARsgen Therapeutics
  • 15.42.1 THANK-uCAR®
  • 15.42.2 CycloCAR®
  • 15.42.3 LADAR®
  • 15.42.4 CARvivo™
  • 15.42.5 CARsgen’s R&D Pipeline
• 15.43 CARTemis Therapeutics GmbH
  • 15.43.1 Core Focus & Partnerships
  • 15.43.2 TQ's CELLfinity Platform
• 15.44 Cartesian Therapeutics
  • 15.44.1 The RNA Armory® Platform
  • 15.44.2 Cartesian’s R&D Programs
• 15.45 Cell-Easy
• 15.46 Cellectis
  • 15.46.1 UCART
  • 15.46.2 Smart CAR-T
• 15.47 Cellepus Therapeutics
  • 15.47.1 Core CAR-T Development & Technology
• 15.48 Cellergy Pharma, Inc.
  • 15.48.1 IgE-Targeting CAR-T Platform Technology
• 15.49 Cellinfinity Bio
  • 15.49.1 Core Technology and Innovations
  • 15.49.2 Key Therapeutic Pipeline
• 15.50 Cellipont Bioservices
  • 15.50.1 Core Competencies in CAR-T & Cell Therapy
  • 15.50.2 Facilities & Infrastructure
  • 15.50.3 Notable CAR-T Industry Partnerships
• 15.51 Cell Therapies Pty Ltd
  • 15.51.1 Key CAR-T Services
• 15.52 Celluris
  • 15.52.1 RefuaPepCAR (RfuCAR) Technology
• 15.53 Celularity Inc.
  • 15.53.1 Placental-Derived Advantage
    • 15.53.1.1 Off-the-Shelf (Allogeneic) Capabilities
  • 15.53.2 Key Pipeline Assets
  • 15.53.3 Proprietary Technology Platform
• 15.54 Celyad Oncology SA
  • 15.54.1 shRNA-Based Allogeneic Platform
• 15.55 Century Therapeutics
  • 15.55.1 Allo-Evasion Technology
  • 15.55.2 R&D Focus
• 15.56 Chimera Bioengineering
  • 15.56.1 Core Technology & Platforms
  • 15.56.2 Focus in CAR-T Therapy
• 15.57 Chimeric Therapeutics
  • 15.57.1 CHM
  • 15.57.2 The 3rd Generation CAR-T
• 15.58 Circio Holding ASA
  • 15.58.1 How Circio's Platform Relates to CAR-T
  • 15.58.2 Strategic Partnerships & Pipeline
• 15.59 COEPTIS Therapeutics
  • 15.59.1 SNAP-CAR Technology
  • 15.59.2 How SNAP-CAR Works
    • 15.59.2.1 Key Benefits of the Technology
    • 15.59.2.2 Current Applications and Development
• 15.60 CREATE Medicines
  • 15.60.1 Key CAR-T Programs
• 15.61 CrisprBits
  • 15.61.1 CrisprBits in the Context of CAR-T Cell Therapies
• 15.62 CRISPR Therapeutics AG
  • 15.62.1 CRISPR/cas9
  • 15.62.2 Key Allogeneic CAR-T Candidates
• 15.63 Crown Bioscience
  • 15.63.1 Crown Bio's CAR-T Services
• 15.64 Curocell
  • 15.64.1 OVIS™ (Overcome Immune Suppression) Platform
  • 15.64.2 Solid Tumor CAR-T Platform
  • 15.64.3 Allogeneic (Off-the-Shelf) CAR-T Technology
  • 15.64.4 R&D Programs
• 15.65 Currus Biologics Pty Ltd
• 15.66 Cyteph Pty Ltd
  • 15.66.1 Core Technology: Cyt-ATTAC Platform
    • 15.66.1.1 CYT-AT1
• 15.67 Cytoart, Inc.
  • 15.67.1 CAR-T Related Services
• 15.68 Dispatch Bio
  • 15.68.1 Core Technology: The Flare™ Platform
  • 15.68.2 Clinical Pipeline & Partnerships
• 15.69 Dynamic Cell Therapies, Inc.
  • 15.69.1 Core Technology: Controllable CAR-T System
  • 15.69.2 Therapeutic Pipeline & Indications
• 15.70 EdiGene
  • 15.70.1 Core Technology Platforms
  • 15.70.2 Key Pipeline Programs
• 15.71 Editas Medicine
  • 15.71.1 SLEEK Technology
  • 15.71.2 Editas Medicine’s CAR-Programs
• 15.72 Elicera Therapeutics AB
  • 15.72.1 iTANK Technology
  • 15.72.2 Key Product Pipeline Candidates
• 15.73 Eli Lilly
  • 15.73.1 Strategic Acquisitions and Pipeline
  • 15.73.2 The Shift to In Vivo Technologies
• 15.74 Elpis Biopharmaceuticals
  • 15.74.1 Proprietary Technology Platforms
  • 15.74.2 Lead CAR-T Pipeline Candidates
  • 15.74.3 Key Partnerships and Clinical Trials
• 15.75 Epigenic Therapeutics
  • 15.75.1 EPIREG® Platform
  • 15.75.2 Epigenic Therapeutics & CAR-T Cell Therapy
  • 15.75.3 Core Technology Platforms
• 15.76 EsoBiotec
  • 15.76.1 The ENaBL Platform
  • 15.76.2 Pipeline & Clinical Status
• 15.77 Essen BioTech
• 15.78 Eureka Therapeutics
  • 15.78.1 CAR-T Product Candidate
• 15.79 EVA Pharma
  • 15.79.1 Moves in CAR-T Therapy
• 15.80 EXUMA Biotech
  • 15.80.1 GCAR Platform
  • 15.80.2 rPOC SC Platform
  • 15.80.3 CD3-Targeted LVV
  • 15.80.4 Tumor Metabolism Regulated (TMR) CARs
  • 15.80.5 FITNESS DRIVER
  • 15.80.6 Synthetic CAR Ligands (SCL)
  • 15.80.7 EXUMA Biotech’s R&D Pipeline
• 15.81 FastBack Bio
  • 15.81.1 M-STIM Platform
• 15.82 Fate Therapeutics
  • 15.82.1 1XX CAR Technology
  • 15.82.2 Sword and Shield™ Technology
  • 15.82.3 Alloimmune Defense Receptor (ADR) Technology
  • 15.82.4 CAR-T-Based R&D Programs
• 15.83 Fosun Pharma
  • 15.83.1 Key CAR-T Milestones and Corporate Strategy
  • 15.83.2 Patient Accessibility and Affordability
• 15.84 Galapagos NV
  • 15.84.1 Galapago’s “Pont-of-Care” CAR-T Platform
• 15.85 Gencyte Therapeutics
  • 15.85.1 PMA CAR Technology
• 15.86 Genentech Inc.
  • 15.86.1 Current CAR-T Collaborations and Focus
• 15.87 Gilead Sciences
  • 15.87.1 Key CAR-T Marketed Therapies
  • 15.87.2 Strategic Pipeline and Growth
• 15.88 Gennova Biopharmaceuticals
  • 15.88.1 Gennova's Role in CAR-T Cell Therapy
  • 15.88.2 Gennova's Strategic Direction
• 15.89 GlycoMantra
  • 15.89.1 Context in CAR-T Cell Therapy
• 15.90 GoCART Therapeutics
  • 15.90.1 Technology & Platform
• 15.91 Gracell Biotechnologies
  • 15.91.1 FasTCAR
  • 15.91.2 TrUCAR
  • 15.91.3 SMART CART
  • 15.91.4 Key Clinical Programs
• 15.92 Guangzhou Biogene Biotech Co., Ltd.
  • 15.92.1 Rapid Target Screening and Validation Platform
  • 15.92.2 Rapid Autologous CAR-T Manufacturing Platform
  • 15.92.3 Off-the-shelf CAR-T Platform
  • 15.92.4 In Vivo Modified CAR-T Platform
  • 15.92.5 Guangzhou Bio-gene’s R&D Pipeline
• 15.93 Gyala Therapeutics
  • 15.93.1 Key Pillars of Gyala Therapeutics' Focus
• 15.94 IASO Biotherapeutics
  • 15.94.1 Equecabtagene Autoleucel (eque-cel)
• 15.95 iCell Gene Therapeutics, LLC
  • 15.95.1 Compound CARs (cCARs)
  • 15.95.2 Non-Gene Editing CAR Technology
  • 15.95.3 Universal CARs (Super NK-Cells)
  • 15.95.4 Universal CARs (Super NK-Cells)
• 15.96 Immuneel Therapeutics
  • 15.96.1 Qartemi (varnimcabtagene autoleucel)
• 15.97 ImmunoACT
  • 15.97.1 NexCAR19 (Talicabtagene autoleucel)
• 15.98 Immunofoco
  • 15.98.1 Peri Cruiser® Platform
  • 15.98.2 SolidGuard
  • 15.98.3 Lentiviral-based In Vivo CAR-T Platform
  • 15.98.4 Immunofoco’s R&D Pipeline
• 15.99 Immunopharm Technology Co., Ltd.
  • 15.99.1 Core Focus & Pipeline
• 15.100 Inceptor Bio
  • 15.100.1 OUTLAST Platform
  • 15.100.2 IBT-101
• 15.101 Innovative Cellular Therapeutics
  • 15.101.2 CoupledCAR® Platform Technology
  • 15.101.3 INSTACAR™ Platform
  • 15.101.4 ARMOREDCAR™ Platform
  • 15.101.5 InvivoCAR Platform
  • 15.101.6 R&D Programs
• 15.102 Intellia Therapeutics
  • 15.102.1 Universal CAR-T
  • 15.102.2 Intellia Therapeutics’ CAR-T R&D Programs
• 15.103 Invectys, Inc.
  • 15.103.1 Core Technology & Pipeline
• 15.104 iO BiO Sciences
  • 15.104.1 Technology Platform
  • 15.104.2 Clinical & Therapeutic Focus
• 15.105 Janssen Pharmaceuticals
  • 15.105.1 Flagship Therapy: Carvykti (Cilta-cel)
  • 15.105.2 Key Partnerships and Pipeline
• 15.106 Jiangsu Pacific Meinuoke Biopharmaceuticals Co., Ltd.
  • 15.106.1 Key CAR-T Programs in the Pipeline
• 15.107 JW Therapeutics
  • 15.107.1 Key Products & Pipeline
• 15.108 Kelonia Therapeutics
  • 15.108.1 iGPS® Platform
• 15.109 Kincell Bio
  • 15.109.1 Core Focus Areas in the CAR-T Space
  • 15.109.2 Facilities and Infrastructure
• 15.110 Kiragen Bio
  • 15.110.1 KiraLOGIC Platform
• 15.111 Kite Pharma
  • 15.111.1 Yescarta® (axicabtagene ciloleucel)
  • 15.111.2 Tecartus® (brexucabtagene autoleucel)
  • 15.111.3 Bicistronic CAR-T Therapy
• 15.112 Kytopen Corp
  • 15.112.1 Kytopen's Role & Technology
  • 15.112.3 Key CAR-T Partnerships & Milestones
• 15.113 Kyverna Therapeutics
  • 15.113.1 SmarTcell™ platform
  • 15.113.2 Ingenui-T™ Manufacturing Platform
• 15.114 Legend Biotech Corporation
  • 15.114.1 Core Technology Platforms
    • 15.114.2.1 CARVYKTI® (ciltacabtagene autoleucel)
  • 15.114.3 Pipeline Candidates
• 15.115 Leman Biotech Co., Ltd.
  • 15.115.1 Clinical Breakthroughs
  • 15.115.2 Core Technology & Partnerships
• 15.116 Leucid Bio
  • 15.116.1 Lateral CAR-T Platform
  • 15.116.2 Pipeline Lead Asset: LEU011
• 15.117 Liminatus Pharma
  • 15.117.1 Core Therapeutics & Pipeline
• 15.118 Link Cell Therapies
  • 15.118.1 Logic-Gated CAR-T
• 15.119 Luminary Therapeutics
  • 15.119.1 Technology
• 15.120 Lyell Immunopharma
  • 15.120.1 Key Reprogramming Technologies
  • 15.120.2 Lyell Immunopharma's R&D Programs
• 15.121 March Biosciences, Inc.
  • 15.121.1 Pipeline & Technology
• 15.122 MaxCyte, Inc.
  • 15.122.1 The ExPERT GTx® system
  • 15.122.2 Company Focus and Core Technology
  • 15.122.3 Strategic Impact of ExPERT GTx on CAR-T and Cell Therapy
  • 15.122.4 Industry Adoption of ExPERT GTx
• 15.123 MedTherapy Biotech
  • 15.123.1 Core Services & Platforms
• 15.124 Miltenyi Biomedicine GmbH
  • 15.124.1 CliniMACS Prodigy® system
  • 15.124.2 Miltenyi Biotec’s CAR-T Product Pipeline
• 15.125 Minerva Biotechnologies
• 15.126 Mustang Bio
  • 15.126.1 Key Clinical Programs
  • 15.126.2 Proprietary Manufacturing Facility
• 15.127 Nexcella, Inc.
  • 15.127.1 NXC-201
• 15.128 Noile-Immune Biotech Inc.
  • 15.128.1 PRIME Technology
  • 15.128.2 Key Pipeline Candidates
• 15.129 Novartis International AG
  • 15.129.1 T-Charge™ Platform
  • 15.129.2 Kymriah® (tisagenlecleucel)
• 15.130 Novatim Immune Therapeutics
  • 15.130.1 The IRAE Bifunctional antibody Platform
  • 15.130.2 Nanoantibody Screening Platform
  • 15.130.3 K2 CAR-T Platform
  • 15.130.4 Novatim’s R&D Pipeline
• 15.131 OneChain Immunotherapeutics
• 15.132 OncoC4, Inc.
  • 15.132.1 Role in CAR-T Cell Therapy
• 15.133 Optieum Biotechnologies
  • 15.133.1 Eumbody System™
• 15.134 OriCell Therapeutics
  • 15.134.1 Key Products & Pipeline
• 15.135 Orna Therapeutics
  • 15.135.1 The Circular RNA (oRNA) Platform
  • 15.135.2 Primary Target Areas
• 15.136 Outpace Bio
  • 15.136.1 OUTSMART™ Technology
  • 15.136.2 OUTLAST™ Technology
  • 15.136.3 OUTSPACERS™ Technology
  • 15.136.4 OUTSAFE™ Technology
  • 15.136.5 OUTDRIVE™ Technology
  • 15.136.6 R&D Programs
• 15.137 PeproMene Bio
  • 15.137.1 Core Technologies
    • 15.137.1.1 BAFFR-CAR T cells (PMB-CT01)
    • 15.137.1.2 BAFFR CAR-NK Cells
    • 15.137.1.3 BAFFR Bispecific T Cell Engager (BiTE)
    • 15.137.1.4 High-Polyfunctionality CAR Platform
  • 15.137.2 Key CAR-T-Based Clinical Trials
• 15.138 Poseida Therapeutics
  • 15.138.1 Technologies
  • 15.138.2 piggyBac™ DNA Modification System
  • 15.138.3 Cas-CLOVER™ Site-Specific Gene Editing
  • 15.138.4 Allogeneic (TSCM)-Rich Platform
  • 15.138.5 Booster Molecule Technology
    • 15.138.5.1 Solid Tumor & Dual CAR Capabilities
  • 15.138.6 Key Pipeline Programs
• 15.139 Precigen
  • 15.139.1 Core CAR-T Technologies
  • 15.139.2 Key Clinical Programs
• 15.140 Precision Biosciences
  • 15.140.1 Key Features of Precision's CAR-T Platform
• 15.141 Prescient Therapeutics Ltd
  • 15.141.1 OmniCAR Platform
  • 15.141.2 CellPryme-M
  • 15.141.3 CellPryme-A
  • 15.141.4 PTX-100
• 15.142 Priothera, Ltd.
  • 15.142.1 Role in CAR-T and Cellular Therapy
• 15.143 ProMab Biotechnologies, Inc.
  • 15.143.1 Core CAR-T Custom Services
• 15.144 PromiCell
  • 15.144.1 IL-18 Cytokine Armoring (SAVVY-IL18 Platform)
• 15.145 Regeneron
• 15.146 Roche Group
  • 15.146.1 Acquisitions & Strategic Direction
  • 15.146.2 Key CAR-T Programs
  • 15.146.3 Target Indications
• 15.147 Sana Biotechnology
  • 15.147.1 Key CAR-T-Based Technologies
  • 15.147.2 Hypoimmune (HIP) Platform (Allogeneic)
  • 15.147.3 Fusogen Platform
  • 15.147.4 Ex Vivo Cell Engineering
• 15.148 Senti Bio
  • 15.148.1 Core Technology: Gene Circuits & Logic Gates
  • 15.148.2 Pipeline & Clinical Focus
  • 15.148.3 Clinical Status & Regulatory Designations
• 15.149 Shenzhen MagicRNA Biotechnology Co., Ltd.
  • 15.149.1 Technology Platform
  • 15.149.2 Product Pipeline & Therapeutics
• 15.150 Shenzhen Pregene Biopharma Co., Ltd.
  • 15.150.1 Key CAR-T Program
  • 15.150.2 PRG-1801 (anti-BCMA CAR-T)
• 15.151 Simnova Biotherapeutics
  • 15.151.1 BiTE-Armed CAR-T Cells
• 15.152 Strand Therapeutics
  • 15.152.1 In Vivo Cell Programming
  • 15.152.2 The SignalLock and SignalPath Systems
  • 15.152.3 Repeat Dosing and Safety
  • 15.152.4 Therapeutic Indications
• 15.153 Synlico, Inc.
• 15.154 TC Biopharm
  • 15.154.1 Gamma Delta T (GDT) Cell Platform
  • 15.154.2 Co-Stim CAR-T Platform
  • 15.154.3 CryoTC Technology
  • 15.154.4 ImmuniCAR® Platform
  • 15.154.5 TC Biopharm’s Clinical Programs
• 15.155 T-CURX GmbH
  • 15.155.1 Sleeping Beauty
  • 15.155.2 Key CAR-T Product Candidate Pipeline
• 15.156 Terumo BCT
  • 15.156.1 Quantum Flex
• 15.157 TG Therapeutics
  • 15.157.1 CAR-T Pipeline & Focus
• 15.158 Thermo Fisher Scientific
  • 15.158.1 Core Tools and Instrumentation for CAR-T Workflows
  • 15.158.2 Media, Reagents, and Analytics
  • 15.158.3 End-to-End CDMO and CRO Services
• 15.159 Tikva Allocell Pte Ltd
  • 15.159.1 Core Technology & Pipeline
• 15.160 TriArm Therapeutics
  • 15.160.1 FIT™ (Fast-In-Time)
  • 15.160.2 FlexTune™
  • 15.160.3 OppoTAGs (Adaptors) Technology
  • 15.160.4 CD30+ FineTune™ Technology
  • 15.160.5 CD3ε FlowTune™ Technology
  • 15.160.6 Key Clinical Programs
• 15.161 T-Maximum Pharmaceutical
  • 15.161.1 Core Focus & Pipeline
• 15.162 Ucello Therapeutics
  • 15.162.1 CBT-X20™ Technology Platform
  • 15.162.2 Key Product Candidates
• 15.163 Umoja Biopharma
  • 15.163.1 VivoVec™ In Vivo Delivery Platform
  • 15.163.2 RACR™/CAR In Vivo Cell Expansion/Control Platform
  • 15.163.3 TumorTag™ Targeting Platform
  • 15.163.4 Umoja’s R&D Programs
• 15.164 Vector BioMed, Inc.
  • 15.164.1 The LENTIVERSE Platform
  • 15.164.2 Context and Global Impact in CAR-T
    • 15.164.2.1 Regional Deployment in India
• 15.165 Verismo Therapeutics
  • 15.165.1 KIR-CAR Platform
  • 15.165.2 R&D Programs
• 15.166 Vittoria Biotherapeutics
  • 15.166.1 Senza5™ Technology
• 15.167 Waypoint Bio
  • 15.167.1 Core Technology & Approach
  • 15.167.2 Key Therapeutic Programs
• 15.168 Wugen, Inc.
  • 15.168.1 Wugen's CAR-T Program
• 15.169 Xcell Biosciences
  • 15.169.1 AVATAR™ Platform
  • 15.169.2 AVATAR Odyssey™ (Research System)
  • 15.169.3 AVATAR Ai™ (Software)
• 15.170 Xenetic Biosciences, Inc.
  • 15.170.1 Key CAR-T Initiatives
  • 15.170.2 Clinical & Strategic Milestones
• 15.171 Xyphos Biosciences
  • 15.171.1 convertibleCAR-T™
• 15.172 YolTech Therapeutics
  • 15.172.1 Core Focus